¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative value scales"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative convergence
    »ó´ë´«¸ðÀ½
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    »ó´ëºóµµ, ºñ±³ºóµµ
  • relative hearing
    »ó´ëÀûû°¨
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª
  • relative leukocytosis
    »ó´ëÀû¹éÇ÷±¸Áõ°¡(Áõ)
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative motion
    »ó´ë¿îµ¿
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • relative scotoma
    »ó´ë¾ÏÁ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • symbolic value
    »ó¡°¡Ä¡
  • value system
    °¡Ä¡Ã¼°è
  • threshold value
    ¹®Åΰª, ¿ªÄ¡
  • typical value
    ´ëǥġ
  • value
    °ª, °¡Ä¡, Ä¡
  • relative acidosis
    »ó´ëÀû»êÁõ
  • relative convergence
    »ó´ë´«¸ðÀ½
  • relative afferent pupillary defect
    ºñ±³µé½Å°æµ¿°ø°á¼Õ
  • relative risk estimation
    »ó´ëÀ§ÇèµµÃßÁ¤
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è
  • relative hearing
    »ó´ëÀûû°¨
  • relative humidity
    »ó´ë½Àµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • recombination value
    Àç°áÇÕ°ª.
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è<--ģô>
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è<--ģô>
  • hearing, relative
    »ó´ëÀû û°¨
  • radiation,relative biologic effectiveness(rbe)
    »ó´ëÀû(ºñ±³Àû)»ý¹°ÇÐÀûÈ¿°ú(ßÓÓßîÜ(ÝïÎòîÜßæÚªùÊîÜüùÍý)
  • relative accommodation
    »ó´ëÁ¶Àý(ÝïÎòðàï½).
  • relative acidosis
    »ó´ëÀû »êÁõ(ßÓÓßîÜß«ñø).
  • relative afferent pupillary defect
    »ó´ëÀû±¸½É¼ºµ¿°ø¿îµ¿Àå¾Ö
  • relative biologic effectiveness of radiation
    ¹æ»ç¼±ÀÇ»ó´ëÀû»ý¹°ÇÐÀûÈ¿°ú(Û¯ÞÒàÊ¡­ßÓÓßîÜßæÚªùÊîÜüùÍý)
  • relative biological effectiveness
    »ó´ëÀû »ý¹°ÇÐÀû È¿°ú(ßÓÓßîÜßæÚªùÊîÜüù
  • relative biological effectiveness
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£)
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • end dilution value =EDV
    ü¿ÜÈñ¼®Ä¡(ô÷èâýüà·ö·).
  • ester value
    ¿¡½ºÅͰª.
  • exceptional value
    ¿¹¿ÜÄ¡(ËçËí̬).
  • expected value
    ±â´ëÄ¡(Ë»ËÀ̬).
  • first degree relative
    ÀϵîÄ£(ìéÔõöÑ).
  • gamma value
    °¨¸¶Ä¡
  • group reference value
    Áý´Ü±âÁØ<--ÂüÁ¶>Ä¡
  • half value layer =HVL
    [¾È°ú]¹Ý°¡Ãþ(Úâʤöµ).
  • half-value layer
    ¹Ý°¡Ãþ
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è<--ģô>
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è<--ģô>
  • hearing, relative
    »ó´ëÀû û°¨
  • hematocrit value
    Ç츶ÅäÅ©¸®Æ®°ª.
  • hydrogen value
    ¼ö¼Ò°¡(â©áÈʤ).
  • hydroxyl value
    ÇÏÀ̵å·Ï½Ç°ª.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • caloric value
    Ä®·Î¸® °ª
  • Cot value
    Cot Ä¡(ö·)
  • C value
    C °ª
  • C value paradox
    C °ª ÆÄ¶óµ¶½º
  • dilution value of buffer
    ¿ÏÃæ¾× Èñ¼®°¡(èÐõúäûýüà·Ê¤)
  • D value
    D °ª (ÔÒ) decimal reduction time
  • ester value
    ¿¡½ºÅÍ °ª
  • F value
    F °ª
  • g value
    g °ª
  • G value
    G °ª
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • half-value layer
    ¹Ý°¨Ãþ(ÚâÊõöµ)
  • hydroxyl value
    ÇÏÀ̵å·Ï½Ç°ª
  • Kirschner value
    Ű½´³Ê°ª
  • probability value
    È®·ü(ü¬×Ë) °ª
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RVI relative value index; right ventricle infarction
RVS rectovaginal space; relative value scale/study; reported visual sensation; retrovaginal space
RVU relative value unit
RF radial fiber; radio frequency; receptive field; regurgitant fraction; Reitland-Franklin [unit]; rela...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BV Biological Value
EBV Estimated breeding value
MV Maturation Value
NPV Negative Predictive Value
NPV Net Present Value
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mean value
    Æò±ÕÄ¡
  • molar buffer value
    ¸ô ¿ÏÃæ°¡
  • negative predictive value
    À½¼º ¿¹»óÄ¡
  • normal value
    Á¤»óÄ¡, Ç¥ÁØÄ¡, ±ÔÁ¤Ä¡
  • observed value
    °üÃøÄ¡
  • osmotic value
    »ïÅõ °ª
  • symbolic value
    »ó¡ °¡Ä¡
  • threshold value
    ¿ªÄ¡
    ½Å°æÀ̳ª ±ÙÀ° µî¿¡ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â µ¥ ÇÊ¿äÇÑ ÃÖ¼Ò ÀÚ±Ø °ª. ÃÖ¼Ò ÇÑ°è °ªÀ̶ó°íµµ ÇÑ´Ù. ÀÛ¿ë ¿øÀο¡ µû¶ó ¿ªÄ¡ÀÇ Á¾·ùµµ ¿©·¯ °¡Áö°¡ ÀÖ´Ù. ÀÚ±Ø ÀÛ¿ëÀÏ ¶§´Â ÀڱؿªÀ̶ó Çϰí, ±× Áß¿¡¼­µµ °¨°¢ Á¾·ù¿¡ µû¶ó ½Ã°¢¿ª, û°¢¿ªÀ̶ó°í ºÎ¸¥´Ù. ÀÌµé °ªÀº »ýü°¡ ÀÚ±ØÀ» ¹Þ¾Æ ÈïºÐÀ» ³ªÅ¸³»´Â ´É·Â, Áï ÈïºÐ¼ºÀÇ Ã´µµ·Î »ïÀ» ¼öµµ ÀÖ´Ù. ÀÚ±Ø È¿°ú´Â ±× °­µµ»Ó ¾Æ´Ï¶ó, ÀÚ±ØÀÇ Áö¼Ó ½Ã°£À̳ª °­µµÀÇ ½Ã°£Àû °æ°ú¿¡ µû¶ó Á¿ìµÈ´Ù. ¶Ç, ¼Ò¸®³ª ºû°ú °°ÀÌ ÀÛ¿ë ¿øÀÎÀÇ ¾çÀûÀÎ Â÷°¡ ÀÚ±Ø È¿°ú¿Í °°Àº °æ¿ì´Â ½Äº°¿ªÀ̶óµçÁö ±¸º°¿ªÀ̶ó Çϰí, ¾çÀûÀÎ Â÷¸¦ ¹®Á¦ ½ÃÇÏÁö ¾Ê´Â ÀÏ¹Ý ¿ªÄ¡¸¦ ´Ü¼ø¿ªÀ̶ó°í ÇÑ´Ù.
  • value judgement
    °¡Ä¡ ÆÇ´Ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
relative leukocytosis An increased proportion of one or more types of leukocytes in the circulating blood, without an actual increase in the total number of white blood cells.
(05 Mar 2000)
relative molecular mass The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units.
See: atomic weight.
Synonym: molecular mass, molecular weight ratio, relative molecular mass.
(05 Mar 2000)
relative polycythemia A relative increase in the number of red blood cells as a result of loss of the fluid portion of the blood.
(05 Mar 2000)
relative refractory period The period between the effective refractory period and the end of the refractory period; fibres then respond only to high intensity stimuli and the impulses conduct more slowly than normally.
(05 Mar 2000)
relative risk <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased.
(05 Dec 1998)
relative scotoma A scotoma in which there is visual depression but not complete loss of light perception.
(05 Mar 2000)
relative sensitivity The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test.
(05 Mar 2000)
relative specificity The specificity of a medical screening test as determined by comparison with the same type of test (e.g., specificity of a new serological test relative to specificity of an established serological test).
(05 Mar 2000)
relative viscosity The ratio of the viscosity of a solution or dispersion to the viscosity of the solvent or continuous phase.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
acetyl value The milligrams of KOH required to neutralise the acetic acid produced by the hydrolysis of 1 g of acetylated fat; a measure of the hydroxy acids present in glycerides; notably high in castor oil.
(05 Mar 2000)
beta, or beta-value <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor.
See: pressure, kinetic pressure, magnetic pressure, second stability.
(09 Oct 1997)
biological value <nutrition> The nutritional value of a protein, usually measured in comparison to the nutritional value of egg protein, which is the highest possible (BV=0.9 - 1.00).
(21 Mar 1998)
buffer value The power of a substance in solution to absorb acid or alkali without change in pH; this is highest at a pH value equal to the pKa value of the acid of the buffer pair.
See: buffer capacity.
Synonym: buffer index.
(05 Mar 2000)
buffer value of the blood The ability of the blood to compensate for additions of acid or alkali without disturbance of the pH.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • absolute value
    Àý´ë°ª
  • atomic value
    ¿øÀÚ°¡
  • atonic value
    ¿øÀÚ°¡
  • book value
    ÀåºÎ°¡°Ý
  • calorific value
    ¹ß¿­·®
  • cash (surrender) value
    ÇØ¾à ¹Ýȯ±Ý(º¸Çè °è¾à ÇØ¾à½Ã ¹ÝȯµÇ´Â ±Ý¾×)
  • exchange value
    (°æ)±³È¯ °¡Ä¡
  • expected value
    (Åë°è)±â´ë°ª
  • face value
    ¾×¸é °¡°Ý;±Ç¸é¾×;¾×¸é(Ç¥¸é)»óÀÇ °¡Ä¡(ÀǹÌ)
  • food value
    (½ÄǰÀÇ) ¿µ¾ç°¡
  • market value
    ½ÃÀå °¡°Ý
  • market value GNP
    ½Ã°¡ ±âÁØÀÇ ±¹¹Î ÃÑ»ý»ê 
  • news value
    º¸µµ °¡Ä¡
  • nominal value
    (Áõ±ÇµûÀ§ÀÇ) ¾×¸é°¡°Ý
  • nuisance value
    °ñÅÁ¸ÔÀÌ´Â °¡Ä¡(È¿°ú);(¼Ò±Ô¸ð Æø°ÝµîÀÇ)¹æÇØ È¿°ú 9
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á